James F. Young Sells 5,400 Shares of Novavax, Inc. (NASDAQ:NVAX) Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 5,400 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Novavax Stock Up 3.3 %

Shares of NASDAQ:NVAX opened at $8.85 on Friday. The firm has a market cap of $1.42 billion, a P/E ratio of -3.92 and a beta of 2.07. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The business has a fifty day simple moving average of $8.69 and a 200 day simple moving average of $11.34.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same period last year, the business posted ($1.26) earnings per share. The business’s revenue was down 54.8% on a year-over-year basis. As a group, equities research analysts expect that Novavax, Inc. will post -1.44 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Banque Cantonale Vaudoise raised its position in shares of Novavax by 500.0% in the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,500 shares in the last quarter. Amalgamated Bank raised its position in shares of Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,036 shares in the last quarter. Signaturefd LLC raised its position in shares of Novavax by 214.5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC bought a new stake in Novavax in the 2nd quarter valued at about $152,000. 53.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NVAX. B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. Finally, Jefferies Financial Group lowered their target price on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Novavax currently has a consensus rating of “Hold” and an average target price of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.